Metformin treatment for Type 2 diabetes in pregnancy?

被引:22
作者
Simmons, David [1 ,2 ]
机构
[1] Addenbrookes Hosp, Wolfson Diabet & Endocrinol Clin, Inst Metab Sci, Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 2QQ, England
[2] Univ Melbourne, Dept Rural Hlth, Shepparton, Vic, Australia
关键词
Type; 2; diabetes; Pregnancy; Metformin; Glucose; Malformation; Insulin; Macrosomia; Pre-eclampsia; POLYCYSTIC-OVARY-SYNDROME; ORAL HYPOGLYCEMIC AGENTS; RELEASE METFORMIN; HUMAN-MILK; WOMEN; INSULIN; MELLITUS; THERAPY; RISK; MANAGEMENT;
D O I
10.1016/j.beem.2010.05.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metformin lowers blood glucose by reducing hepatic glucose output, increasing insulin sensitivity and enhancing peripheral glucose uptake. Metformin is widely used in women with Type 2 diabetes of child-bearing age, many of whom become pregnant. Studies to date in Type 2 diabetes in pregnancy, gestational diabetes and polycystic ovarian syndrome are reassuring. Metformin is not considered teratogenic. There is sufficient evidence that metformin is safe used throughout pregnancy, with no worsening of obstetric or perinatal outcomes. Women may benefit from the lesser weight gain. The long-term risks to the offspring remain inadequately researched, with no evidence of harm up to 2 years, and no suggestions of later complications in countries using metformin for many years. Metformin is recommended for use in pregnancies complicated by Type 2 diabetes, but women should be informed of the evidence regarding its associated risks and benefits to enable an informed choice over its use. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:625 / 634
页数:10
相关论文
共 50 条
  • [41] Updates in the Management of Type 1 Diabetes in Pregnancy
    Mazori, Alon Y.
    Levy, Carol J.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2024, 53 (03) : 321 - 333
  • [42] Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes
    Frias, Juan Pablo
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2019, 14 (02) : 75 - 83
  • [43] Cost-effectiveness analysis of metformin plus dipeptidyl peptidase-4 inhibitors compared to metformin plus sulfonylureas for treatment of type 2 diabetes
    Kwon, Christina S.
    Seoane-Vazquez, Enrique
    Rodriguez-Monguio, Rosa
    BMC HEALTH SERVICES RESEARCH, 2018, 18
  • [44] Dapagliflozin for the treatment of type 2 diabetes
    Abdul-Ghani, Muhammad A.
    DeFronzo, Ralph A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (12) : 1695 - 1703
  • [45] Kynurenine pathway in type 2 diabetes: Role of metformin
    Al-Qahtani, Zainah
    Al-kuraishy, Hayder M.
    Ali, Naif H.
    Elewa, Yaser Hosny Ali
    Batiha, Gaber El-Saber
    DRUG DEVELOPMENT RESEARCH, 2024, 85 (05)
  • [46] Metformin increases plasma ghrelin in Type 2 diabetes
    Doogue, Matthew P.
    Begg, Evan J.
    Moore, M. Peter
    Lunt, Helen
    Pemberton, Chris J.
    Zhang, Mei
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (06) : 875 - 882
  • [47] Type 2 diabetes, insulin treatment and prognosis of breast cancer
    Mu, Lan
    Zhu, Nannan
    Zhang, Jiao
    Xing, Fang
    Li, Daiqing
    Wang, Xin
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33 (01)
  • [48] Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis
    Rokkas, T.
    Portincasa, P.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 33 : 60 - 66
  • [49] A narrative review of metformin in pregnancy: Navigating benefit and uncertainty
    McEvoy, Robert P.
    Newman, Christine
    Egan, Aoife M.
    Dunne, Fidelma P.
    DIABETES OBESITY & METABOLISM, 2025,
  • [50] Effect of metformin on glycaemic control in patients with type 1 diabetes: A meta-analysis of randomized controlled trials
    Meng, Haiyang
    Zhang, Ailing
    Liang, Yan
    Hao, Jie
    Zhang, Xiaojian
    Lu, Jingli
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34 (04)